GRIN2A | Glutamate receptor, ionotropic, N-methyl D-aspartate 2A | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/22725/151909_B_7_4_rna_selected_60x60.jpg) | Tissue enhanced |
HDAC6 | Histone deacetylase 6 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | ![](/images/3714/ihc_cell_selected_60x60.jpg) | ![](/images/26321/57610_A_3_2_rna_selected_60x60.jpg) | Expressed in all |
HMGCR | 3-hydroxy-3-methylglutaryl-CoA reductase | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/8338/ihc_cell_selected_60x60.jpg) | ![](/images/8338/23048_A_6_1_rna_selected_60x60.jpg) | Expressed in all |
HSD3B1 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 | Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/43261/103681_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
HSD3B2 | Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/43261/103681_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/14011/142185_B_8_1_rna_selected_60x60.jpg) | Tissue enriched |
HTR2B | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/12867/31386_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
HTR7 | 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins RAS pathway related proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/22708/53493_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
ICAM1 | Intercellular adhesion molecule 1 | Cancer-related genes Candidate cardiovascular disease genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images/2142/if_selected_60x60.jpg) | | ![](/images/2142/5934_B_7_3_rna_selected_60x60.jpg) | Expressed in all |
IL2RA | Interleukin 2 receptor, alpha | Cancer-related genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/2419/ihc_cell_selected_60x60.jpg) | ![](/images/2419/6368_B_7_3_rna_selected_60x60.jpg) | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/62657/139409_B_8_4_rna_selected_60x60.jpg) | Tissue enhanced |
IL2RG | Interleukin 2 receptor, gamma | Cancer-related genes CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/46641/107861_B_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
ITGA2B | Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/31168/73887_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
ITGAL | Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/25011/57822_B_8_1_rna_selected_60x60.jpg) | Expressed in all |
ITGAV | Integrin, alpha V | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins
| | ![](/images/4856/if_selected_60x60.jpg) | | ![](/images/4856/13045_B_8_6_rna_selected_60x60.jpg) | Expressed in all |
ITGB1 | Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) | Cancer-related genes CD markers FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | ![](/images/3434/9046_B_7_8_rna_selected_60x60.jpg) | Expressed in all |
KCNA10 | Potassium voltage-gated channel, shaker-related subfamily, member 10 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | ![](/images/22564/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/15061/34147_B_7_3_rna_selected_60x60.jpg) | Not detected |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/21516/109609_B_7_2_rna_selected_60x60.jpg) | Group enriched |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/42434/134323_B_1_7_rna_selected_60x60.jpg) | Tissue enhanced |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images/47634/ihc_cell_selected_60x60.jpg) | ![](/images/47634/111871_B_8_5_rna_selected_60x60.jpg) | Tissue enriched |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/18656/42007_B_1_3_rna_selected_60x60.jpg) | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | ![](/images/57112/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/57112/140451_B_8_1_rna_selected_60x60.jpg) | Group enriched |
KDR | Kinase insert domain receptor (a type III receptor tyrosine kinase) | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | ![](/images/30893/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/4028/11466_B_8_5_rna_selected_60x60.jpg) | Mixed |
KIT | V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | ![](/images_static/na_center.gif) | | ![](/images/3288/8263_A_3_6_rna_selected_60x60.jpg) | Mixed |
LHCGR | Luteinizing hormone/choriogonadotropin receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | ![](/images/9814/ihc_cell_selected_60x60.jpg) | ![](/images/9814/31107_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
MAOA | Monoamine oxidase A | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/9437/30396_B_9_2_rna_selected_60x60.jpg) | Mixed |
MAOB | Monoamine oxidase B | Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | ![](/images/2328/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/2328/7274_B_9_4_rna_selected_60x60.jpg) | Mixed |
MGAM | Maltase-glucoamylase (alpha-glucosidase) | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/2270/8419_B_8_5_rna_selected_60x60.jpg) | Group enriched |
MME | Membrane metallo-endopeptidase | Cancer-related genes Candidate cardiovascular disease genes CD markers Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/13/117_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | | ![](/images/14341/39080_B_8_5_rna_selected_60x60.jpg) | Group enriched |
MS4A2 | Membrane-spanning 4-domains, subfamily A, member 2 | FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/59967/ihc_cell_selected_60x60.jpg) | ![](/images/59967/135063_B_7_2_rna_selected_60x60.jpg) | Mixed |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images/14509/ihc_cell_selected_60x60.jpg) | ![](/images/14509/34609_B_4_5_rna_selected_60x60.jpg) | Group enriched |
P2RY12 | Purinergic receptor P2Y, G-protein coupled, 12 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/14518/33943_B_8_2_rna_selected_60x60.jpg) | Tissue enriched |
PDGFRB | Platelet-derived growth factor receptor, beta polypeptide | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | ![](/images/28499/if_selected_60x60.jpg) | | ![](/images/3842/10176_B_9_3_rna_selected_60x60.jpg) | Mixed |
PROS1 | Protein S (alpha) | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images/23974/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/23974/53791_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
PSMD1 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images/36736/if_selected_60x60.jpg) | | ![](/images/36737/126709_B_9_6_rna_selected_60x60.jpg) | Expressed in all |
PSMD2 | Proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 | FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images/45192/if_selected_60x60.jpg) | | ![](/images/45192/100075_B_8_1_rna_selected_60x60.jpg) | Expressed in all |
RYR1 | Ryanodine receptor 1 (skeletal) | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/56416/ihc_cell_selected_60x60.jpg) | ![](/images/56416/140329_B_8_2_rna_selected_60x60.jpg) | Tissue enriched |
SI | Sucrase-isomaltase (alpha-glucosidase) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/11897/141363_B_8_3_rna_selected_60x60.jpg) | Group enriched |
SIGMAR1 | Sigma non-opioid intracellular receptor 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | | ![](/images/13470/31433_B_3_4_rna_selected_60x60.jpg) | Expressed in all |
SLC12A1 | Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images/18107/if_selected_60x60.jpg) | ![](/images/14967/ihc_cell_selected_60x60.jpg) | ![](/images/14967/33483_B_8_2_rna_selected_60x60.jpg) | Tissue enriched |
SLC12A3 | Solute carrier family 12 (sodium/chloride transporter), member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/28748/141823_A_3_6_rna_selected_60x60.jpg) | Tissue enriched |
SLC22A8 | Solute carrier family 22 (organic anion transporter), member 8 | FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/44174/ihc_cell_selected_60x60.jpg) | ![](/images/44174/147449_A_7_6_rna_selected_60x60.jpg) | Tissue enriched |
SLC5A2 | Solute carrier family 5 (sodium/glucose cotransporter), member 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images/41603/ihc_cell_selected_60x60.jpg) | ![](/images/41603/148722_B_8_3_rna_selected_60x60.jpg) | Tissue enriched |
SLC6A1 | Solute carrier family 6 (neurotransmitter transporter), member 1 | FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images/13341/if_selected_60x60.jpg) | ![](/images_static/rna_center.gif) | ![](/images/22293/56979_B_8_5_rna_selected_60x60.jpg) | Group enriched |
SLC8A1 | Solute carrier family 8 (sodium/calcium exchanger), member 1 | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/22694/49717_B_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
SOAT1 | Sterol O-acyltransferase 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | ![](/images/47171/146636_B_8_3_rna_selected_60x60.jpg) | Tissue enriched |
SSTR1 | Somatostatin receptor 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | ![](/images_static/rna_center.gif) | ![](/images/31506/140928_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
SV2A | Synaptic vesicle glycoprotein 2A | FDA approved drug targets Predicted membrane proteins
| | | | ![](/images/2226/6002_B_9_2_rna_selected_60x60.jpg) | Tissue enriched |
TBXAS1 | Thromboxane A synthase 1 (platelet) | Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | ![](/images_static/rna_center.gif) | ![](/images/31259/67793_A_3_6_rna_selected_60x60.jpg) | Mixed |